Jefferies Maintains Merck & Co. to Hold with Price Target $56.00

Brokerage firm Jefferies Maintains its rating on Merck & Co.(NYSE:MRK). In a research note issued to the investors, the brokerage major Lowers the price-target to $56.00 per share. The shares have been rated Hold. The rating by Jefferies was issued on Sep 12, 2016.

In a different note, On Sep 9, 2016, Barclays said it Maintains its rating on Merck & Co.. In the research note, the firm Raises the price-target to $66.00 per share. The shares have been rated ‘Overweight’ by the firm. On Aug 19, 2016, UBS said it Maintains its rating on Merck & Co.. In the research note, the firm Raises the price-target to $62.00 per share. The shares have been rated ‘Buy’ by the firm. On Aug 8, 2016, Jefferies said it Maintains its rating on Merck & Co.. In the research note, the firm Raises the price-target to $53.00 per share. The shares have been rated ‘Hold’ by the firm. On Aug 8, 2016, Deutsche Bank said it Maintains its rating on Merck & Co.. In the research note, the firm Raises the price-target to $58.00 per share. The shares have been rated ‘Hold’ by the firm. On Aug 5, 2016, BMO Capital said it Upgrades its rating on Merck & Co.. In the research note, the firm Raises the price-target to $62.00 per share. The shares have been rated ‘Outperform’ by the firm. On Jul 18, 2016, BMO Capital said it Downgrades its rating on Merck & Co.. The shares have been rated ‘Market Perform’ by the firm.

Merck & Co. (MRK) made into the market gainers list on Tuesdays trading session with the shares advancing 0.99% or 0.61 points. Due to strong positive momentum, the stock ended at $61.94, which is also near the day’s high of $62.41. The stock began the session at $61.9 and the volume stood at 92,11,610 shares. The 52-week high of the shares is $64 and the 52 week low is $47.97. The company has a current market capitalization of $171,277 M and it has 2,76,52,08,200 shares in outstanding.

Merck & Co.(MRK) last announced its earnings results on Jul 29, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $9.84B. Analysts had an estimated revenue of $9.79B. Earnings per share were $0.93. Analysts had estimated an EPS of $0.91.

Several Insider Transactions has been reported to the SEC. On Sep 1, 2016, Adam H Schechter (EVP & Pres-Global Human Health) sold 39,200 shares at $62.61 per share price.Also, On Aug 10, 2016, Clark Golestani (EVP & Chief Info Officer) sold 3,000 shares at $63.03 per share price.On Aug 5, 2016, Kenneth C Frazier (Chairman, President & CEO) sold 392,000 shares at $61.95 per share price, according to the Form-4 filing with the securities and exchange commission.

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Merck & Co. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Merck & Co.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.